Results of the study on Injectable Antiretroviral, was published in The Lancet and the International Meeting of the AIDS Society in Paris
It is not a cure, but reduces to a simple monthly injection all treatment!]
ViiV Healthcare, the world's leading HIV specialist on GSK's property, with a Pfizer Inc. and Shionogi Limited as shareholders, today announced data from the 96 study weeks related to the antiretroviral Injectable. LATTE-2 is a Phase IIb, open-label study of injectable formulations of cabotagravir (ViiV Healthcare) and long-acting rilpivirine (Janssen Science Ireland UC) as a two-drug treatment for patients with HIV-1 infection who have already achieved a viral suppression regimen with an oral regimen of three blocking drugs plus two nucleoside reverse transcriptase inhibitors (NRTIs). The results of the study were published online in The Lancet and so many at the annual conference of the International AIDS Society (IAS) in Paris, France.
Fixed-dose oral treatments that contain three or more drugs with advanced HIV treatment, reducing the burden of pills and providing convenience for people living with HIV. As far as HIV is concerned, adherence to therapy remains essential for viral suppression and to reduce the onset of resistance mutations. The Latte-2 trial sought to evaluate the injectable antiretroviral regimen consisting of injectable cabotegravir and rilpivirine given once every four to eight weeks compared to the daily oral dosage with cabotegravir + 2 TTR.
After 96 weeks of maintenance treatment in the LATTE-2 study, viral suppression rates (%) for the two-week (94%) or four-week (87%) twice weekly injectable regimens were comparable to rate observed in patients who continued with a regimen of three oral antiretrovirals (84%). Two patients in the eight-week dosing group and one patient in the oral regimen group presented signs defined by the protocol of therapeutic failure; no patient showed signs of viral resistance in the therapeutic failure.
O antiretroviral showed good results in the study.
Local injection pain with the injectable antiretroviral was the most commonly reported was the local injection reaction (ISR) reported by patients receiving injectable antiretroviral, plus ISRs were mild (84%) or moderate (15%) in severity, with a medium duration symptom of three days.
John C. Pottage Jr., chief medical officer at ViiV Healthcare, said: "These study results are important because now they show the durability and tolerability of long-acting viral suppression for an infection regimen up to 96 weeks. An Administration of Long-Term Parenteral Medication removed a daily dose load for PATIENTS AND Study Results showed that long-term cabotegravir and rilpivirine maintained a viral suppression with no Therapeutic Failure in any of the Four Week Dosing group. We look forward to results from our Phase III program with Antiretroviral Injection long acting cabotegravir and rilpivirine in 2018. "
Adverse Events of Antiretroviral Injection in the Study!
During the maintenance period, most commonly reported adverse events not related to local injection reactions for the injectable treatment groups were nasopharyngitis (20%), headache (14%) and diarrhea (12%). For patients randomized to oral treatment, the most common adverse events during the maintenance period were nasopharyngitis (25%), headache (7%) and diarrhea (5%). Events adverse events occurred in 6% of patients who received injectable (non-drug-related) treatment and 5% of patients receiving oral cabotegravir (non-drug related). One patient in the eight-week group of injectable treatment died due to an unrelated event to study drugs (seizure). Nine patients withdrew because of adverse events. Laboratory abnormalities that emerged during the maintenance phase (grade 3 ≥ severity) occurred in 16% of injectable treatment patients and 14% of oral treatment patients by mid-week 32.
Note: This study with the Injectable Antiretroviral is what gives me most hope because it is a shocking antiretroviral in quality of life, since it only needs a single application of Antiretroviral Injection and this difference is everything! To learn more read this previous article on long-acting injectable antiretroviral.